Pharmacokinetics of three new β-lactams in the Yucatan micropig model administered by intravenous bolus injection and continuous infusion

International Journal of Antimicrobial Agents

Volumn 8, Issue 2, 1997, Pages 135-141

  Elkhaili H ^a   Leveque D ^a   Peter, J D ^a   Salmon, Y ^a   Salmon, J ^a   Pompei, D ^a   Monteil, H ^a   Jehl, F ^a  

^a Institut de Bacteriologie   (France)

Author keywords

cefepime; cefpirome; meropenem; pharmacodynamic; pharmacokinetic; Yucatan micropig

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFPIROME; MEROPENEM;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; DRUG DETERMINATION; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0343907322     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00367-1     Document Type: Article

References (36)

1. LeBel M, Spino M. Pulse dosing versus continuous infusion of antibiotics: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1988;14:71-95.
2. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother 1992;36:2577-2583.
3. Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 1984;12:241-261.
4. Ritschel WA. In vivo animal models for bioavailability assessment. S.T.P. Pharma 1987;2:125-141.
5. Panepinto LM, Phillips RW. Genetic selection for small body size in Yucatan miniature pigs. Lab Anim Sci 1981;31:403-404.
6. Panepinto LM, Phillip RW. The Yucatan miniature pig: characterization and utilization in biomedical research. Lab Anim Sci 1986;36:344-347.
7. Azria M, Kiger JL. Intérêt du porc miniature en recherche biomédicale. Thérapie 1972;XXVII:723-732.
8. Hughes HC. Swine in cardiovascular research. Lab Anim Sci 1986;36:348-350.
9. Levêue D, Peter JD, Salmon J, Salmon Y, Elkhaïli H, Kaltenbach G, Cavalier A, Jehl F. Modèle de microporc cathétérisé pour les études pharmacocinétiques des agents anticancéreux. Bull Cancer 1995;82:412.
10. Elkhaili H, Linger L, Monteil H, Jehl F. High-performance liquid chromatographic assay for cefepime in serum. J Chromatogr B 1997 (in press).
11. Elkhaili H, Niedergang S, Pompei D, Linger L, Levêque D, Jehl F. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B 1996;686:19-26.
12. Gibaldi M, Perrier D. Pharmacokinetics, Vol. 15, Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1982.
13. Kurihara-Bergstrom T, Woodworth M, Feisullin S, Beal P. Characterization of the Yucatan miniature pig skin and small intestine for pharmaceutical applications. Lab Anim Sci 1986;36:396-399.
14. Bustad LK, McClellan RO. Use of pigs in biomedical research. Nature 1965;208:531-536.
15. Badian M, Malerczyk V, Collins JD, Dixon GT, Verho M, Eckert HG. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing. Chemotherapy 1988;34:367-373.
16. Barbhaiya RH, Forgue ST, Gleason CR, Knupp C, Pittman KA, Weidler DJ, Martin RR. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother 1990;34:1118-1122.
17. Forgue ST, Shyu WC, Gleason CR, Pittman KA, Barbhaiya RH. Pharmaeokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys. Antimicrob Agents Chemother 1987;31:799-804.
18. Klesel N, Seeger K. Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in Animals. Infection 1983;11:318-322.
19. Burman L, Nilsson-Ehle I, Hutchinson M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother 1991;27:219-224.
20. Jehl F, Bresler L, Koechlin C, Merle-Melet M, Didelot JP, Hazebroucq J. Pharmacokinetics and biliary elimination of temafloxacin in pigs. J Antimicrob Chemother 1992;30:189-196.
21. Levêque D, Merle-Melet M, Bresler L, Didelot JP, Aymard JP, Wihlm J, Jehl F. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 1993;32:487-490.
22. Oberle RL, Das H, Wong SL, Chan KKH, Sawchuk RJ. Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. Pharmaeol Res 1994;1:698-703.
23. Swagler AR, Qian M, Gall JM. Pharmacokinetics of anti-HIV nucleosides in microswine. J Pharm Pharmacol 1991;43:823-826.
24. Kaltenbach G, Levêque D, Peter JD, Salmon J, Elkhaïli H, Cavalier A, Salmon Y, Monteil H, Jehl F. Pharmacokinetic interaction between itraconazole and rifampin in two Yucatan miniature pigs. Antimicrob Agents Chemother 1996;40:2043-2046.
25. Levêque D, Elkhaïli H, Peter JD, Linger L, Salmon J, Cavalier A, Salmon Y, Monteil H, Jehl F. Pharmacokinetics of vinorelbine in a chronic model of catheterized micropig. Pharm Res 1996;13:S-484.
26. Levêque D, Elkhaïli H, Peter JD, Cavalier A, Salmon J, Linger L, Dillenseger R, Salmon Y, Monteil H, Jehl F. Profil pharmacocinétique de la ceftriaxone chez le pore miniature. 7e Congrès de Pharmacie Clinique. Bordeaux 9-10 Février 1996.
27. Van den Brock JM, Teunissen MWE, Breimer DD. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metab Dispos 1981;9:541-544.
28. Bodey GP, Ho DH, LeBlanc B. In vitro studies of BMY-28142, a new broad spectrum cephalosporin. Antimicrob Agents Chemother 1985;27:265-269.
29. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 1985;27:679-682.
30. Bosso JA, Saxon BA, Matsen JM. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginsa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother 1991;35:783-784.
31. Huls CE, Prince RA, Seilheimer DK, Bosso JA. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993;37:1414-1416.
32. Jones RN, Pfaller MA, Allen SD, Gerlach EH, Fuchs PC, Aldridge KE. Antimicrobial activity of cefpirome: an update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diag Microbiol Infect Dis 1991;14:361-364.
33. Neu HC, Chin NX, Labthavikal P. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae, and Pseudomonas aeruginosa. Infection 1985;13:146-155.
34. Edwards JR, Turner PJ, Wannop C, Withnell EW, Grindey AJ, Nairin K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase-I. Antimicrob Agents Chemother 1989;33:215-222.
35. Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988;10:892-898.
36. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimirob Chemother 1989;24(Suppl. A):265-277.